Article
Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy.
Antiviral therapy - 1 Jan 2012
Liu Chen-Hua, Liang Cheng-Chao, Liu Chun-Jen, Tseng Tai-Chung, Lin Chih-Lin, Yang Sheng-Shun, Su Tung-Hung, Hsu Shih-Jer, Lin Jou-Wei, Chen Jun-Herng, Chen Pei-Jer, Chen Ding-Shinn, Kao Jia-Horng
Abstract excerpt
BACKGROUND: Interleukin 28B (IL28B) single nucleotide polymorphism (SNP) genotypes and viral factors can predict sustained virological response (SVR) in HCV genotype-1 (HCV-1) patients receiving 48 weeks of pegylated interferon and ribavirin. Whether these factors would identify those patients wh...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.